Overview

Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.

Status:
Not yet recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the safety and efficacy of combination therapy involving β3-adrenoceptor agonist, mirabegron, and α-blockers for the treatment of OAB symptoms in male patients with BPH.

Phase:

Phase 4

Details

Lead Sponsor:

St. Joseph's Healthcare Hamilton

Treatments:

Mirabegron
Tamsulosin